Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CASR | P41180 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10364314 | 1.00 | CYP2D6 (0.58) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| Fumaric Acid SCHEMBL10363331 | 0.93 | CYP2D6 (0.54) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| Fumaric Acid SCHEMBL10363329 | 0.93 | CYP2D6 (0.54) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| Maleic Acid SCHEMBL10363327 | 0.93 | CYP2D6 (0.54) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| SCHEMBL10363360 | 0.89 | CYP2D6 (0.56) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| SCHEMBL10750728 | 0.88 | CYP2D6 (0.55) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| SCHEMBL13204483 | 0.84 | ADRB1 (0.73) | CYP2D6ADRB2ADRB1NR3C1ADRA1A | |
| SCHEMBL10732729 | 0.82 | CYP2D6 (0.67) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| SCHEMBL10363672 | 0.81 | CYP2D6 (0.61) | CYP2D6ADRB2ADRB1ADRB3CA12 | |
| SCHEMBL10365218 | 0.81 | ADRB2 (0.62) | CYP2D6ADRB2ADRB1ADRB3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4665094-A | GLAUCOMA | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | claimed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | Accencio LLC | 2023-04-13 | — | — | US | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12453717-B1 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CYP2D6 429/4885ADRB2 2686/4885ADRB1 2063/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CYP2D6 1279/4885ADRB2 3605/4885ADRB1 2744/4885 |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | ACE, ACE2, TMPRSS2 | CYP2D6 1279/4885ADRB2 3605/4885ADRB1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.